Sonoma Pharmaceuticals, Inc. (SNOA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of SNOA were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No SNOA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SNOA short interest
Low short interest. 1.4% of SNOA shares are sold short: about 1 share in 72. Over the last 12 reports the number of shares short went up 147%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 66,674 SNOA shares were sold short, 1.4% of the shares outstanding, down 38.7% from the report before. At the average daily volume of 39,962 shares, buying them all back would take about 1.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 66,674 | 1.39% | -39% | 39,962 | 1.7 |
| Oct 15, 2026 | 108,814 | 2.27% | -34% | 39,300 | 2.8 |
| Sep 30, 2026 | 164,505 | 3.44% | -18% | 53,832 | 3.1 |
| Sep 15, 2026 | 201,492 | 4.21% | +11% | 45,281 | 4.5 |
| Aug 31, 2026 | 182,313 | 3.81% | -9% | 77,306 | 2.4 |
| Aug 14, 2026 | 201,048 | 4.20% | +2280% | 399,785 | 1.0 |
| Jul 31, 2026 | 8,448 | 0.18% | -83% | 31,236 | 1.0 |
| Jul 15, 2026 | 49,784 | 1.04% | -40% | 87,989 | 1.0 |
| Jun 30, 2026 | 82,827 | 1.73% | +1724% | 262,246 | 1.0 |
| Jun 15, 2026 | 4,540 | 0.09% | -90% | 92,782 | 1.0 |
| May 29, 2026 | 45,360 | 2.62% | +68% | 165,199 | 1.0 |
| May 15, 2026 | 27,047 | 1.56% | -96% | 106,890 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Sonoma Pharmaceuticals company events
Sonoma Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 6, 2026.
- Oct 6, 2026AgreementSigned an important agreement. Filing
- Sep 17, 2026VoteReported shareholder vote results. Filing
- Aug 19, 2026VoteReported shareholder vote results. Filing
- Jun 18, 2026AnnouncementAs previously reported, on September 26, 2025, Sonoma Pharmaceuticals, Inc. entered into an At Market Issuance Sales Agreement, with Ladenburg Thalmann & Co. Inc., pursuant to which the Company may offer and sell, from time to time, through Ladenburg, as agent, shares of its common stock, $0.0001… Filing
- Apr 30, 2026AgreementSonoma Pharmaceuticals, Inc. entered into an underwriting agreement with Dawson James Securities, Inc. Filing
- Apr 9, 2026AgreementWe entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn ® technology-based products in the United States. Filing
- Jan 28, 2026LeadershipDeparture of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Jan 12, 2026AnnouncementAttached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates. Filing
- Jan 2, 2026LeadershipDeparture of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Sonoma Pharmaceuticals financials
Famous investors that hold SNOA
2 of the 50 well-known investors we track reported holding SNOA in their latest 13F filing. The largest position is Jim Simons's, worth $99.1K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 77,400 | $99.1K | 0.0% | +91% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 67,965 | $87K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Sonoma Pharmaceuticals, Inc. (SNOA) stock
Are SNOA insiders buying or selling?
No SNOA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in SNOA?
As of Oct 30, 2026, 66,674 SNOA shares were sold short, 1.4% of the shares outstanding, down 38.7% from the report before. At the average daily volume of 39,962 shares, buying them all back would take about 1.7 trading days (days to cover). See the history.
Which famous investors hold SNOA?
2 of the 50 well-known investors we track reported SNOA in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $99.1K. See all holders.
Executive pay
Sonoma Pharmaceuticals's chief executive was paid a total of $741K for the year ended Mar 31, 2026, up 24% from $597K the year before. In the last 12 months, Sonoma Pharmaceuticals's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.